-
公开(公告)号：US20130029983A1
公开(公告)日：2013-01-31
申请号：US13497697
申请日：2010-09-22
申请人： Carlo Ballatore , Kurt R. Brunden , Alexander L. Crowe , Donna M. Huryn , Virginia M.Y. Lee , John Q. Trojanowski , Amos B. Smith, III , Ruili Huang , Wenwei Huang , Ronald L. Johnson , Francesco Piscitelli
发明人： Carlo Ballatore , Kurt R. Brunden , Alexander L. Crowe , Donna M. Huryn , Virginia M.Y. Lee , John Q. Trojanowski , Amos B. Smith, III , Ruili Huang , Wenwei Huang , Ronald L. Johnson , Francesco Piscitelli
IPC分类号： A61K31/5025 , C07D495/04 , A61K31/5377 , A61P25/28 , A61P25/16
CPC分类号： C07D495/04 , A61K31/5025 , A61K31/5377
摘要： The present invention is directed to methods of inhibiting a tauopathy in a patient by administration of a compound of formula I: Novel aminothienopyridazine compounds are also described.
摘要翻译： 本发明涉及通过给药式I化合物来抑制患者的tau蛋白病变的方法：还描述了新的氨基噻吩并哒嗪化合物。
-
公开(公告)号：US20120329877A1
公开(公告)日：2012-12-27
申请号：US13489745
申请日：2012-06-06
申请人： Onur Atasoylu , Carlo Ballatore , Kurt R. Brunden , Longchun Huang , Donna M. Huryn , Michael James , Virginia M.Y. Lee , Francesco Piscitelli , Amos B. Smith, III , James Soper , John Q. Trojanowski
发明人： Onur Atasoylu , Carlo Ballatore , Kurt R. Brunden , Longchun Huang , Donna M. Huryn , Michael James , Virginia M.Y. Lee , Francesco Piscitelli , Amos B. Smith, III , James Soper , John Q. Trojanowski
CPC分类号： C07C311/17 , A61K31/18 , C07C2601/02 , C07C2601/04 , C07C2601/10 , C07C2601/14 , C07D257/04
摘要： The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R1 is H or C1-6alkyl and R2 is H, C1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and X is O or N; as well as tautomers and pharmaceutically acceptable salt forms thereof. Uses of these compounds are also described.
摘要翻译： 本发明涉及式I化合物：其中A是n是0,1或2; m为0或1; R 1是H或C 1-6烷基，R 2是H，C 1-6烷基，取代或未取代的芳基或取代或未取代的杂芳基; X为O或N; 以及互变异构体及其药学上可接受的盐形式。 还描述了这些化合物的用途。
-
3.发明申请Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor 审中-公开新型四氢萘并呋喃对血栓素A2（TP）受体的拮抗剂公开(公告)号：US20130190370A1
公开(公告)日：2013-07-25
申请号：US13812793
申请日：2011-07-27
申请人： John Q. Trojanowski , Virginia M.Y. Lee , Kurt R. Brunden , Amos B. Smith , Donna M. Huryn , Carlo Ballatore , Anne-Marie Hogan , Francesco Piscitelli
发明人： John Q. Trojanowski , Virginia M.Y. Lee , Kurt R. Brunden , Amos B. Smith , Donna M. Huryn , Carlo Ballatore , Anne-Marie Hogan , Francesco Piscitelli
IPC分类号： C07C311/20 , C07D317/28 , A61K31/196 , A61K45/06 , A61K31/18 , A61K31/41 , A61K31/357 , C07D257/04 , A61K31/216
CPC分类号： A61K31/18 , A61K31/196 , A61K31/216 , A61K31/357 , A61K31/41 , A61K31/4174 , A61K31/421 , A61K31/426 , A61K45/06 , C07C311/20 , C07D233/64 , C07D257/04 , C07D263/32 , C07D277/28 , C07D317/28
摘要： The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.
摘要翻译： 本发明涉及TP受体拮抗剂，其具有结合TP受体并任选地穿过血脑屏障的能力。 本发明还提供用于治疗其中TP受体活化是有害的病症的组合物和方法。
-
公开(公告)号：US08530520B2
公开(公告)日：2013-09-10
申请号：US13489745
申请日：2012-06-06
申请人： Onur Atasoylu , Carlo Ballatore , Kurt R. Brunden , Longchuan Huang , Donna M. Huryn , Michael James , Virginia M. Y. Lee , Francesco Piscitelli , Amos B. Smith, III , James Soper , John Q. Trojanowski
发明人： Onur Atasoylu , Carlo Ballatore , Kurt R. Brunden , Longchuan Huang , Donna M. Huryn , Michael James , Virginia M. Y. Lee , Francesco Piscitelli , Amos B. Smith, III , James Soper , John Q. Trojanowski
IPC分类号： A61K31/18
CPC分类号： C07C311/17 , A61K31/18 , C07C2601/02 , C07C2601/04 , C07C2601/10 , C07C2601/14 , C07D257/04
摘要： The present invention is directed to carboxylic acid-containing pharmaceutical compounds where the carboxylic acid moieties have been substituted with cycloalkyl-dione derivatives, as well as tautomers and pharmaceutically acceptable salt forms thereof. These bioisosteric replacements improve the compound's ability to effectively cross the blood brain barrier and result in improved pharmacokinetic, toxicological, and/or safety profiles.
摘要翻译： 本发明涉及羧酸部分已被环烷基二酮衍生物取代的含羧酸的药物化合物，以及其互变异构体及其药学上可接受的盐形式。 这些生物电泳替代物可以改善化合物有效跨越血脑屏障的能力，并改善药代动力学，毒理学和/或安全性。
-
公开(公告)号：US20130337463A1
公开(公告)日：2013-12-19
申请号：US13882674
申请日：2011-11-04
申请人： Kurt R. Brunden , Virginia M.Y. Lee , John Q. Trojanowski , Kelvin C. Luk , Jing Guo , Laura Volpicelli-Daley
发明人： Kurt R. Brunden , Virginia M.Y. Lee , John Q. Trojanowski , Kelvin C. Luk , Jing Guo , Laura Volpicelli-Daley
CPC分类号： G01N33/6896 , G01N33/5058
摘要： The present invention relates to a cell-based model useful for identifying molecules that modify intracellular pathways of α-synuclein and tau aggregation and degradation.
摘要翻译： 本发明涉及用于鉴定修饰α-突触核蛋白的细胞内途径和tau聚集和降解的分子的基于细胞的模型。
-
公开(公告)号：US20090263824A1
公开(公告)日：2009-10-22
申请号：US12412015
申请日：2009-03-26
CPC分类号： C07K16/18 , G01N33/6896 , G01N2800/2821 , G01N2800/52
摘要： Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided.
摘要翻译： 提供了评估受试者中缺乏或存在神经变性疾病的方法，包括在受试者的组织样品中表征TDP-43。 还公开了用于诊断受试者中的神经变性疾病的方法以及用于测定药物抵抗神经变性疾病的功效的方法。 还提供了结合TDP-43的新型抗体。
-
公开(公告)号：US20100209417A1
公开(公告)日：2010-08-19
申请号：US12085427
申请日：2006-11-21
IPC分类号： A61K39/395 , C07K16/00 , C12N5/07 , A61P25/28
CPC分类号： C07K16/18 , A61K39/3955 , G01N33/53
摘要： Provided is an antibody that selectively binds to an epitope formed by residues 1-11 of Aβ in an Aβ oligomer, a method comprising using the antibody to treat a disease characterized by such an Aβ amyloid deposit in a patient, and kits comprising same.
摘要翻译： 提供了选择性结合由A＆bgr的残基1-11形成的表位的抗体; 在A＆bgr 低聚物，包括使用该抗体治疗以这样的A＆Bgr为特征的疾病的方法; 患者中的淀粉样蛋白沉积物和包含其的试剂盒。
-
8.发明授权公开(公告)号：US06358681B2
公开(公告)日：2002-03-19
申请号：US09183636
申请日：1998-10-30
IPC分类号： C12Q168
CPC分类号： C12Q1/6883
摘要： Methods of detecting RNA in brain tissue of patients with Alzheimer's disease are provided. Methods of diagnosing Alzheimer's disease by detection of these RNAs are also provided.
摘要翻译： 提供了检测阿尔茨海默病患者脑组织RNA的方法。 还提供了通过检测这些RNA来诊断阿尔茨海默氏病的方法。
-
公开(公告)号：US5849988A
公开(公告)日：1998-12-15
申请号：US261810
申请日：1994-06-17
CPC分类号： C07K14/4711 , A01K67/027 , Y10S530/839
摘要： Methods of generating a rat having A.beta. deposits in the brain of the rat by injecting an amount of human A68 protein sufficient to result in formation of the deposits and subsequently examining the rat for the formation of the deposits are disclosed. Rats characterized by the presence of A.beta. deposits similar to those found in individuals with Alzheimer's disease are also disclosed. Methods of screening test compositions for prophylactic or therapeutic activity by generating a rat having A.beta. deposits in its brain, treating the animal with the test composition and examining the animal for therapeutic or prophylactic effectiveness are also disclosed.
摘要翻译： 公开了通过注射足以导致沉积物形成并随后检查大鼠以形成沉积物的量的人A68蛋白来产生大鼠脑中具有Aβ沉积物的大鼠的方法。 特征在于存在类似于在阿尔茨海默病个体中发现的Aβ的沉积物的大鼠也被公开。 还公开了通过在其脑中产生具有Aβ沉积物的大鼠来筛选测试组合物用于预防或治疗活性的方法，用测试组合物治疗动物并检查动物的治疗或预防效力。
-
公开(公告)号：US5601985A
公开(公告)日：1997-02-11
申请号：US495308
申请日：1995-06-27
CPC分类号： G01N33/6896 , G01N2800/2821 , Y10S435/96 , Y10S436/811
摘要： Antibodies specifically reactive with an abnormally phosphorylated peptide comprising SEQ ID NO: 3 wherein a serine in SEQ ID NO: 3 is abnormally phosphorylated are provided. Methods of detecting abnormally phosphorylated .tau. in a test sample and methods of diagnosing Alzheimer's Disease with these antibodies are also provided.
摘要翻译： 提供了与包含SEQ ID NO：3的异常磷酸化肽特异性反应的抗体，其中SEQ ID NO：3中的丝氨酸异常磷酸化。 还提供了测试样品中异常磷酸化tau检测方法和用这些抗体诊断阿尔茨海默病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.041 秒)
